Aimei Health Technology Co., Ltd. (AFJK) - 10-Q Summary
Business Context and Reporting Period
Aimei Health Technology Co., Ltd. is a Cayman Islands exempted company and a "blank check" SPAC formed to pursue a business combination with healthcare innovation targets. The reporting period covers the three and nine months ended September 30, 2025. The Company has not yet commenced operations and generates no operating revenue; its activities are limited to organizational costs and pursuing a merger. The Company is classified as an emerging growth company and a shell company.
Key Financial Metrics
| Metric | 9 Months Ended Sept 30, 2025 | 3 Months Ended Sept 30, 2025 | As of Sept 30, 2025 |
|---|---|---|---|
| Net Income | $961,651 | $352,019 | - |
| Operating Costs | ($585,170) | ($130,152) | - |
| Interest Income (Trust) | $1,546,821 | $482,171 | - |
| Cash (Operating) | - | - | $2,979 |
| Cash in Trust Account | - | - | $45,443,570 |
| Total Assets | - | - | $45,468,518 |
| Total Liabilities | - | - | $3,464,428 |
| Working Capital Deficit | - | - | ($2,749,480) |
| Extension Loans (Related Party) | - | - | $1,655,400 |
Material Changes vs. Prior Period
- Redemptions: On February 5, 2025, approximately 2,904,267 shares were redeemed for ~$31.27 million, reducing the Trust Account balance from $73.78 million (Dec 31, 2024) to $45.44 million (Sept 30, 2025).
- Net Income Decline: Net income for the nine months ended Sept 30, 2025 ($961,651) decreased significantly compared to the same period in 2024 ($2,108,102), primarily due to lower interest income earned on the reduced Trust Account balance.
- Liabilities Increase: Total current liabilities increased from $816,994 to $2,774,428, driven by the accumulation of extension loans ($1,655,400) and amounts due to related companies ($826,419) to fund the extension of the business combination deadline.
- Extension Fees: The Company extended its combination deadline twelve times. Extension fees were adjusted from a per-share basis to a flat $150,000 per month for the majority of the extensions in 2025.
Outlook, Risks, and Management Commentary
- Business Combination Status: The Company entered a definitive agreement with United Hydrogen Group Inc. in June 2024. Shareholders approved the combination in November 2025. Closing is expected in early 2026, subject to regulatory clearances.
- Deadline: The Company has extended its deadline to consummate a business combination to December 6, 2025.
- Liquidity: Operating cash is minimal ($2,979). Liquidity is maintained through related party loans (extension notes) and the Trust Account. Management believes current resources are sufficient to meet needs until the combination closes.
- Going Concern: The filing discloses substantial doubt about the Company's ability to continue as a going concern if a business combination is not consummated by the deadline, necessitating liquidation.
- Controls: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025.
Investor Verification Checklist
- Merger Closing Date: Verify if the United Hydrogen merger closes before the December 6, 2025 deadline.
- Extension Funding: Confirm the ability of the Sponsor and United Hydrogen to fund further extension fees if the deadline is not met.
- Redemption Risk: Assess the risk of additional shareholder redemptions prior to closing, which could further deplete the Trust Account.
- Related Party Debt: Review the terms of the $1.65 million in extension loans and their potential conversion into equity upon closing.
- Internal Controls: Investigate the specific deficiencies leading to the ineffective disclosure controls conclusion.